Open AccessHuman cord blood‐derived regulatory T ‐cell therapy modulates the central and peripheral immune response after traumatic brain injury
Author(s) -
Caplan Henry W.,
Prabhakara Karthik S.,
Kumar Akshita,
ToledanoFurman Naama E.,
Martin Cecilia,
Carrillo Louis,
Moreno Nicolas F.,
Bordt Andrea S.,
Olson Scott D.,
Cox Charles S.
Publication year - 2020
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.1002/sctm.19-0444
Subject(s) - neuroinflammation , immune system , medicine , traumatic brain injury , microglia , immunology , inflammation , innate immune system , acquired immune system , neuroscience , biology , psychiatry
Traumatic brain injury (TBI) causes a profound inflammatory response within the central nervous system and peripheral immune system, which contributes to secondary brain injury and further morbidity and mortality. Preclinical investigations have demonstrated that treatments that downregulate microglia activation and polarize them toward a reparative/anti‐inflammatory phenotype have improved outcomes in preclinical models. However, no therapy to date has translated into proven benefits in human patients. Regulatory T cells (Treg) have been shown to downregulate pathologic immune responses of the innate and adaptive immune system across a variety of pathologies. Furthermore, cellular therapy has been shown to augment host Treg responses in preclinical models; yet, studies investigating the use of Treg as a therapeutic for TBI are lacking. In a rodent TBI model, we demonstrate that human umbilical cord blood Treg modulate the central and peripheral immune response after injury in vitro and in vivo.